Arthneeti
All Q2 FY26 results →
QD

Quest Diagnostics Incorporated

Q2 FY26Health Care Providers and Services

Quest Diagnostics Incorporated Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹196
Market cap₹21.7K Cr
P/E21.3
Updated29 May 2026
Read3 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

- Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. - Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%.

From Quest Diagnostics Incorporated's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%.
  • Excluding Corewell and Fresenius partnerships, organic volume growth was 3.8%.
  • Fresenius and Corewell collaborations contribute approximately 7% to organic volume growth.
  • Revenue guidance for 2026 raised to $11.78B to $11.9B, reflecting 6.8% to 7.8% growth.
  • Continued strong growth expected in physician, hospital, and consumer health channels.
  • Advanced diagnostics and consumer health segments show strong double-digit growth.
  • Partnerships and collaborations, including with wellness and wearable companies, expected to further accelerate growth.
  • Higher test per requisition driven by advanced tests and screening options supports revenue per requisition growth.

2 more points from Quest Diagnostics Incorporated's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Quest Diagnostics Incorporated said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • $550 million capital expenditures forecasted for 2026, consistent with 2025 levels (Page 3).
  • Significant portion of capital investments allocated to esoteric labs for capacity upgrades to support advanced diagnostics growth (Page 11).
  • Continued investments in advanced diagnostics, including brain health biomarkers (AB 42/40, ApoE, NFL, p-tau181/217), cardiometabolic testing, and oncology partnerships (Page 11).

2 more points from Quest Diagnostics Incorporated's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Quest Diagnostics Incorporated said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
Insights related to demand and growth can be inferred: - Solid first quarter results indicate strong demand for diagnostic solutions. - Organic volume growth was 10.8% in Q1 2026, showing broad-based utilization increases. - Growth driven by Corewell Health and Fresenius Medical Care collaborations contributing around 7% to volume growth. - Consumer health and wellness partnerships, including wearables and AI-driven testing, are expanding. - Increased longitudinal testing and test-per-patient trends due to AI, wearables, and consumer-initiated testing are expected.

2 more points from Quest Diagnostics Incorporated's call on order book

Create a free account to keep reading this call

Continue your research

Others in Health Care Providers and Services this season

  • BrightSpring Health Services, Inc. (Q2 FY26)

    BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho

  • DaVita Inc. (Q2 FY26)

    DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe

  • Tenet Healthcare Corporation (Q2 FY26)

    Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor

  • Guardant Health, Inc. (Q2 FY26)

    Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding

Compare:vs UnitedHealth Group Incorporatedvs McKesson Corporationvs Elevance Health, Inc.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Quest Diagnostics Incorporated and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Quest Diagnostics Incorporated Q2 FY26 results?

- Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. - Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%.

What is Quest Diagnostics Incorporated share price analysis?

Quest Diagnostics Incorporated currently shows a below-average growth signal. The stock trades at a P/E of 21.3 with a market cap of $21,719. Investors should review the full earnings analysis for detailed insights.

Is Quest Diagnostics Incorporated planning capital expenditure?

- $550 million capital expenditures forecasted for 2026, consistent with 2025 levels (Page 3).

Keep Quest Diagnostics Incorporated on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.